27 May 2015

INTERVENTIONAL NEWS & SIR: TWO CANADIANS AWARDED 2015 SIR FOUNDATION LEADERS IN INNOVATION AWARD.

Society of Interventional Radiology Foundation bestows annual awards

Interventional radiology pioneers receive Leaders in Innovation Award; young investigator, research and philanthropy awards also presented during SIR's Annual Scientific Meeting
Society of Interventional Radiology




FAIRFAX, Virginia--Two visionaries of interventional radiology were recently awarded the Society of Interventional Radiology Foundation Leaders in Innovation Award. The awards, to Lindsay Stuart Machan, M.D.,FRCPC, FSIR, an interventional radiologist at Vancouver Hospital, British Columbia, and Kieran Patrick Murphy, MB BChir BAO(Dublin), FRCPC., FSIR, an interventional radiologist at the University of Toronto, both in Canada, were announced March 4 during the society's Annual Scientific Meeting in Atlanta.
"SIR Foundation award winners demonstrate a passion for medical breakthroughs that improve patient care," said Stephen T. Kee, M.D., MMM, FSIR, 2014-15 foundation board chair. "The Leaders in Innovation Award honors two of our specialty's visionaries who have each created numerous devices and pioneered advances in the treatment of complex conditions," added Kee, who is professor and chief of interventional radiology at Ronald Reagan UCLA Medical Center in California.
Machan, who is also an associate professor of radiology at the University of British Columbia, focuses his practice on infertility and gynecological interventions as well as aortic and peripheral arterial disease. He has designed many devices and played a significant role in Canada's medical technology industry over the last 15 years, and he holds patents on multiple drug and device technologies, including drug-eluting stents.
Murphy, who is vice chair and chief of medical imaging at the University of Toronto, has worked in the area of acute stroke interventions and the assessment of brain perfusion. His devices for vertebroplasty to treat painful spine compressions are in frequent use worldwide.

 (comment: Prof Machan has` 135 Patents;  Prof Murphy has 60 Patents..

INTERVENTIONAL: NEWS May 2015 p.17 reported Prof MURPHY studying effect of oral anti-oxidant reduce DNA injury from ionising radiation "7-pi;l cocktail includes beta-carotine, vit.C.,alpha-lipoic acid,and n-acetyl cysteine.Presented findings at SIR Atlanta meeting.

INTERVENTIONAL NEWS: May 2015 22-23 Profile "LINDSAY MACHAN".

25 May 2015

DAILY MAIL 2215 The New Human

The rich will become ‘God-like cyborgs’: Historian claims the wealthy will transform into a new type of human within 200 years

  • Comments made by Yuval Harari from Hebrew University of Jerusalem
  • Claims humans are unable to resist temptation to 'upgrade' themselves
  • 'It will be the greatest evolution in biology since the appearance of life'
The rich are set to become God-like cyborgs in what could be the 'biggest evolution in biology' since life emerged.
This is according to Yuval Noah Harari, a professor at the Hebrew University of Jerusalem, who believes the radical shift will take place in the next 200 years.
Using biotechnology and genetic engineering, Professor Harari claims the wealthy will transform into a new type of divine, immortal human with complete power over life and death.

The rich are set to become immortal God-like cyborgs in what could be the 'biggest evolution in biology' since life emerged. This is according to Yuval Noah Harari (left), a professor at the Hebrew University of Jerusalem, who believes this radical shift will take place in the next 200 years
The rich are set to become immortal God-like cyborgs in what could be the 'biggest evolution in biology' since life emerged. This is according to Yuval Noah Harari (left), a professor at the Hebrew University of Jerusalem, who believes this radical shift will take place in the next 200 years
He argues that humans are unable to resist the temptation to 'upgrade' themselves, according to a report by Sarah Knapton in the Telegraph.
'We are programmed to be dissatisfied,' said Professor Harari, during a recent speech at the Hay literary festival in Wales.
'Even when humans gain pleasure and achievements it is not enough. They want more and more.
'I think it is likely in the next 200 years or so homo sapiens will upgrade themselves into some idea of a divine being, either through biological manipulation or genetic engineering of by the creation of cyborgs, part organic part non-organic.
Using biotechnology and genetic engineering, Professor Harari claims the wealthy will transform into a new type of human with complete power over life and death
Using biotechnology and genetic engineering, Professor Harari claims the wealthy will transform into a new type of human with complete power over life and death
'It will be the greatest evolution in biology since the appearance of life. Nothing really has changed in four billion years biologically speaking.
'But we will be as different from today's humans as chimps are now from us.'
The technology to do this, however, will be restricted to the very wealthy, claims Professor Harari.
Up until now, he says society has been held together by inventing 'fictions', such as religion, money and the idea of fundamental human rights.

IS THE WORLD HEADING TOWARDS A POST-HUMAN FUTURE? 

British astrophysicist, Sir Martin Rees, believes we are facing an 'inorganic post-human era'
British astrophysicist, Sir Martin Rees, believes we are facing an 'inorganic post-human era'
Artificial intelligence is progressing at a frightening pace leading humanity towards its ultimate destruction.
This is according to British theoretical astrophysicist, Sir Martin Rees, who believes we are facing an 'inorganic post-human era'.
By some estimates, he says, the process will begin in the next 25 years as robots begin to achieve intelligence rivalling that of humans.
Sir Martin, who is one of the world's most eminent astronomers, says that while Earth has existed for 45 million centuries, this century is special.
Over nearly all of Earth's history, threats have come from nature, but from now on, the worst dangers come from us – and specifically artificial intelligence.
He says that by any definition of 'thinking', the amount and intensity that's done by organic human-type brains will, in the far future, be swamped by the intelligence of AI.
'There are chemical and metabolic limits to the size and processing power of organic brains,' wrote Sir Rees, in an opinion piece for the Telegraph. 
'Maybe humans are close to these limits already. But there are no such constraints on silicon-based computers.'
As long as humans believed they relied more and more on these gods they were controllable, he said
'But what we see in the last few centuries is humans becoming more powerful and they no longer need the crutches of the Gods.'
He added that the most interesting place in the world from a religious perspective is not the Middle East but Silicon Valley.
Here, people are developing what he describes as a 'techno-religion' in which they believe death is just a technological problem.
'Now we are saying we do not need God just technology,' he added.

12 May 2015

TALC- (hydrated magnesium silicate)

AJR Am J Roentgenol. 1986 Feb;146(2):295-301.

Talc: understanding its manifestations in the chest.

Abstract

Four distinct forms of pulmonary disease caused by talc have been defined. The first form, talcosilicosis, is caused by talc mined with high-silica-content mineral. Findings in this form are identical with those of silicosis. Talcoasbestosis closely resembles asbestosis and is produced by crystalline talc, generally inhaled with asbestos fibers. Pathologic and radiographic abnormalities are virtually identical with those of asbestosis, including calcifications and malignant tumor formation. The third form, talcosis, caused by inhalation of pure talc, may include acute or chronic bronchitis as well as interstitial inflammation; radiographically, it appears as interstitial reticulations or small, irregular nodules, typical of small-airway obstruction. The fourth form, due to intravenous administration of talc, is usually associated with abuse of oral medications and production of vascular granulomas manifested by consolidations, large nodules, and masses. Radiographic abnormalities associated with talc can be predicted when there is sufficient history of the nature of exposure, including the region of origin of the talc in cases of inhalation. Radiographic changes, such as diaphragmatic plaques, often attributed to both talc and asbestos have not been documented to be caused by talc alone. The author provides review of 18 well-documented cases.

(COMMENT: still used in some baby powders).

09 May 2015

MYELOMA TODAY: Vol 15 No.2 FDA APPROVES REVLIMID( Lenalidomide) for newly dignosed myeloma

REVLIMID with dexamethasone. FDA recommends stem-cell harvesting after the first four cycles of therapy. together with MUCH CLOSER BLOOD-COUNT monitoring.

27 April 2015

SIMPLEXA GROUP A STREP DIRECT ASSAY

FDA Clears the Simplexa™ Group A Strep Direct Test from Focus Diagnostics, a Quest Diagnostics Business
CYPRESS, Calif. and MADISON, N.J., April 15, 2015 /PRNewswire/ -- Focus Diagnostics, the clinical-laboratory products business of Quest Diagnostics (NYSE: DGX), today announced the FDA 510(k) clearance and CLIA moderate-complexity categorization for its Simplexa Group A Strep Direct Kit.  Simplexa Group A Strep Direct is a real-time polymerase chain reaction assay for the detection of Group A Streptococcus bacteria directly from throat swabs. 
The most prevalent form of Group A Streptococcus (GAS) is strep throat (pharyngitis), a condition most common in children aged 5-15. More than 600 million cases of strep pharyngitis are estimated to occur worldwide each year. Sore throat, a common symptom of strep pharyngitis, is responsible for 7.3 million pediatric out-patient visits in the United States.
"Fast, reliable diagnosis of strep can make a world of difference in the effectiveness of treatment for this highly prevalent and painful bacterial infection," said Hollis (Holly) J. Batterman, MD, medical director, infectious diseases, Focus Diagnostics. "Our Simplexa Direct Strep test uses a proprietary technique to provide results in as quickly as an hour, compared to up to two days for culture, and has better specificity than rapid antigen tests, which are prone to false negatives. Faster diagnosis and subsequent treatment can minimize the risks of infection of others, inappropriate use of antibiotics and progression to more advanced and potentially life-threatening disease."
"Simplexa Direct Strep reflects our vision to provide diagnostic insights that help physicians and patients take prompt, well informed actions to achieve a favorable outcome," Dr. Batterman added.
Simplexa tests, designed for use on the 3M Integrated Cycler, employ real-time polymerase chain reaction (PCR) technology to detect DNA or RNA in viruses, bacteria, and other analytes. Using a proprietary chemistry technique that eliminates the nucleic acid extraction process typical of molecular diagnostics, Simplexa tests can produce results in as quickly as an hour.  
The Simplexa Group A Strep Direct test is intended for the in vitro qualitative detection of group A Streptococcus from throat swabs collected from human patients with signs and symptoms of pharyngitis, such as sore throat. Simplexa Group A Strep Direct showed strong performance in clinical studies, with 97.4% sensitivity and 95.2% specificity compared to culture.
The test is also categorized as moderate complexity, enabling some physician offices, community hospitals, health clinics and integrated delivery networks to perform the test directly. Molecular tests are typically categorized as high-complexity, under the Clinical Laboratory Improvement Amendments, and can only be performed in certain reference and complex hospital labs.
"With moderate complexity classification and a streamlined workflow, our Simplexa Direct Strep test could potentially benefit a large number of the many millions of people suspected of strep each year," said Michelle Tabb, PhD, Vice President of Research and Development for Focus Diagnostics. "That's a major advantage over other molecular methods of diagnosing Group A Strep, which may be more labor intensive to perform."
The test was CE marked for distribution in the European Union in February 2015. The test kit is now available directly in the United States and internationally through the global distribution network of Focus Diagnostics.
About Strep Throat Group A Streptococcus (GAS) is a gram-positive bacterium responsible for a wide range of infections. The most prominent of these infections are known as strep throat (pharyngitis), which occur when the bacteria colonizes in the throat. Strep throat is most common in children between ages 5 and 15. Because it shares symptoms, such as painful sore throat and fever, in common with the flu and other respiratory conditions, laboratory testing is an important aid in diagnosis. Untreated strep infections can lead to serious conditions, including Rheumatic fever and Scarlet fever. Strep is typically treated with a course of antibiotics.
About Focus Diagnostics and Simplexa
Focus Diagnostics, Inc., a business of Quest Diagnostics, develops and manufactures the Simplexa line of molecular test products operating on the Integrated Cycler, a compact, portable testing platform, as part of a global collaboration with 3M. Simplexa was the first test kit to be FDA cleared for aiding in the detection and differentiation of the 2009 H1N1 influenza virus in May 2010. Additional Simplexa tests aid in the detection and differentiation of influenza A, influenza B and RSV, Clostridium difficile and HSV 1 & 2. The Simplexa/3M technology has won several industry awards for medical innovation, including twice winning the prestigious Medical Design Excellence Award. In addition to Simplexa, Focus Diagnostics' products sold worldwide include HerpeSelecttype-specific HSV serology and West Nile Virus DxSelect. To learn more or to order Simplexa and other Focus Diagnostics tests, please contact Focus Diagnostics at 800-838-4548 or visit www.Focusdx.com.

22 April 2015

UK DAILY MAIL AUTOSOMAL DOMINANT DOPA-RESPONSIVE DYSTONIA SEGAWA SYNDROME undiagnosed for 30y.

Segawa Syndrome  

Segawa M, Hosaka A, Miyagawa F, Nomura Y, Imai H (1976). "Hereditary progressive dystonia with marked diurnal fluctuation". Advances in neurology 14: 215–33. PMID 945938.

 

Dr Masaya Segawa [1936 - 2014]
Professor Masaya Segawa, MD, PhD, the director of Segawa Neurological Clinic for Children, Tokyo, Japan, died December 14, 2014, at 78. ICNAPedia.

 

 

Abstract

You are reading a NORD Rare Disease Report Abstract. NORD’s full collection of reports on over 1200 rare diseases is available to subscribers (click here for details). We are now also offering two full rare disease reports per day to visitors on our Web site.
NORD is very grateful to Jonathan W. Mink, MD, PhD, Professor of Neurology, Neurobiology & Anatomy, and Pediatrics; Chief, Child Neurology, University of Rochester Medical Center, for assistance in the preparation of this report.

Synonyms of Segawa Syndrome

  • autosomal dominant dopa-responsive dystonia (DRD
  • autosomal dominant segawa syndrome
  • DYT5 dystonia
  • GTP cyclohydrolase 1-deficient dopa-responsive dystonia
  • guanosine triphosphate cyclohydrolase I deficiency
  • progressive dystonia with marked diurnal fluctuation
  • Segawa disease

Segawa syndrome is a rare genetic disorder characterized by an uncoordinated or clumsy manner of walking (abnormal gait) and dystonia. Dystonia is a general term for a group of muscle disorders generally characterized by involuntary muscle contractions that force the body into abnormal, sometimes painful, movements and positions (postures). Dystonia in Segawa syndrome usually affects the legs, but some children may first develop dystonia in the arms. In some cases, usually in adolescents and adults, the symptoms of Segawa syndrome may become noticeably worse or more pronounced in the afternoon and evening than in the morning (marked diurnal fluctuation). The symptoms of Segawa syndrome usually become apparent by around six years of age. Intelligence is not affected. Children with Segawa syndrome usually show a dramatic and sustained improvement when treated with levodopa. Levodopa is an amino acid that is converted to dopamine, a brain chemical that serves as a neurotransmitter. Dopamine is deficient in children with Segawa syndrome. The disorder is caused by mutations of the GCH-1 gene. The GCH-1 gene mutation is inherited as an autosomal dominant trait.

Woman who spent 30 YEARS fighting debilitating cerebral palsy and undergoing operations discovers she has been misdiagnosed - and almost all of her symptoms can be cured by just one pill

  • Jean Sharon Abbott, 38, from Plymouth, Minnesota, was told she had spastic diplegia, a form of cerebral palsy, when she was four-years-old
  • She was 33-years-old when she learned she actually had dopa-responsive dystonia (DRD), a rare muscle disorder that can be treated with one pill 
  • Jean, who was nearly immobile for 30 years, went on a 10-mile hike four months after she was given her new medication, which is known as L-Dopa
  • Despite her misdiagnosis, the mother-of-three insists she feels no resentment or anger about her doctor’s life-altering mistake 
A woman who spent 30 years of her life believing that she suffered from cerebral palsy, only to learn that she had in fact been misdiagnosed and almost all of her symptoms could be cured with just one pill, insists she feels no resentment or anger about her doctor’s life-changing error.
Jean Sharon Abbott, 38, from Plymouth, Minnesota, was told she had spastic diplegia, a form of cerebral palsy, when she was just four-years-old. But after three decades of suffering from muscle spasms, weakness, near immobility, as well as undergoing painful surgical procedures, she learned at the age of 33 that she actually had dopa-responsive dystonia (DRD), a rare, yet treatable, muscle disorder.
'Honestly, I’ve never had any negative thoughts about what I went through,' Jean told Daily Mail Online of her misdiagnosis, which saw her confined to a bed for much of her childhood. 
Scroll down for video  
Life-changing error: Jean Sharon Abbott can be seen recovering from surgery when she was 12-years-old. The 38-year-old has now discovered she was misdiagnosed with spastic diplegia, a form of cerebral palsy 
Life-changing error: Jean Sharon Abbott can be seen recovering from surgery when she was 12-years-old. The 38-year-old has now discovered she was misdiagnosed with spastic diplegia, a form of cerebral palsy 
Different life: Jean, who is pictured with her husband, used a mobility scooter before she was diagnosed as having dopa-responsive dystonia (DRD) and given new medication
Different life: Jean used a mobility scooter before she was diagnosed as having dopa-responsive dystonia (DRD), a rare, yet treatable, muscle disorder
Different life: Jean, who is pictured with her husband (L) and by herself (R), used a mobility scooter before she was diagnosed as having dopa-responsive dystonia (DRD), a rare, yet treatable, muscle disorder
While Jean admitted that there 'plenty of times' she wished she didn't have to deal with the physical symptoms associated with condition, including her dependence on others to complete everyday tasks, she noted that she still had a 'fantastic childhood' - thanks in large part to the unwavering support of her family and friends.
'Even though I had challenges, my parents were so good with dealing with my disability and didn’t “baby” me,' she explained. 'Also, I had true friendships that I never had to question. All of my life experiences made me who I am today - and I like me.'
 'I was expecting no results whatsoever and couldn’t imagine a life any other way
When Jean was first diagnosed with spastic diplegia, she was considered a textbook case, even though her MRIs and CAT scans didn’t show any typical symptoms of the disorder.
And because her neurologist was considered one of the best in the field, second opinions never yielded any other conclusions. 
'I had been seen by one of the best in the country, if not the world, and my parents even took me to the leading hospital in the US for a second opinion,' she recalled. 'They confirmed the spastic diplegia diagnosis and said that my doctor taught all of them.'
Jean said she never questioned her original diagnosis and instead chose to accept her physical struggles and focus on living her life to the best of her ability. 
'I was never one to dwell on my disability or to think about it too much, other than when I was at these doctor appointments,' she said. 'I guess I was too busy trying to live a normal life and having fun with my friends and family.'
By the time she was 12-years-old, Jean underwent a 'very painful' muscle transfer to prevent her knees from knocking together when she walked.
Miracle drug: Jean, who was once nearly immobile, completed a 10-mile hike with her husband (pictured) four months after she started taking her DRD medication known as L-Dopa
Miracle drug: Jean, who was once nearly immobile, completed a 10-mile hike with her husband (pictured) four months after she started taking her DRD medication known as L-Dopa
Happy family: Jean is pictured with her husband and their three children following her correct diagnosis of DRD
Happy family: Jean is pictured with her husband and their three children following her correct diagnosis of DRD
Although she compared the physical agony to open heart surgery, she said she was glad her parents encouraged her to have the procedure, which helped her a great deal and helped to prevent her from tripping over herself when she walked.  
Jean, who said she 'still can't get her knees to touch', noted that she was 'happy that it was a permanent procedure', although she would have done it again if needed.  
When she was in her late twenties, the mother-of-three had a pump implanted in her body to distribute medicine, but when she ended up over-medicated she visited a specialist who would eventually change her life forever.
 'I was never one to dwell on my disability or to think about it too much
Jean's new doctor questioned her original diagnosis and sent her to another neurologist.
Her new neurologist told her she had actually been living with DRD, noting that most of her symptoms would improve or disappear with a daily dose of a medication known as L-Dopa.
The neurologist explained that the symptoms of DRD, including the involuntary muscle contractions and tremors, are often mistaken for cerebral palsy or other disorders.
But Jean 'couldn't imagine having anything other than spastic diplegia' and confessed that she wasn't even going to fill the prescription until her husband persuaded to her to try it.
'When I began taking it, I was the biggest skeptic,' she said. 'I was expecting no results whatsoever and couldn’t imagine a life any other way.' 
Jean was given what she now knows to be her correct diagnosis on Good Friday in 2010 and just two days later, on Easter Sunday, she stood for the first time without assistance.
New world: Jean can be seen using trekking poles during one of her hikes 
New world: Jean can be seen using trekking poles during one of her hikes 
True love: The happy couple posed for a photo when Jean still believed she had spastic diplegia
True love: The happy couple posed for a photo when Jean still believed she had spastic diplegia
It soon became clear that the medication was working better than Jean could have ever imagined.
As she got stronger, her husband began working with her to increase her walking distance and fourth months later, they celebrated their 10th wedding anniversary by traveling the 1,200 mile road around Lake Superior - the location of their first honeymoon.
And not only was Jean able to walk to the touristy locations that she previously had to be carried to, she was actually able to complete a 10-mile hike along with her husband.
 All of my life experiences made me who I am today - and I like me
While Jean said that they took their time and had snacks along the way, she was amazed by her physical accomplishment.
'I was so proud of myself and thought that there are so many people in the world that physically can do stuff like this but choose not to,' she said. 'And I began to think of all the places I would love to travel with my family that wouldn’t have been an option before.'  
And while Jean realized that there are so many things she wants to try now that she can, she still insists that she doesn't have any regrets about receiving her diagnosis so late in life.
As someone who believes that everything happens for a reason, she noted that if she hadn’t been diagnosed with cerebral palsy, she probably would have chosen a different college, meaning she never would have met her husband and had three children with him.
'All I know is, I’ve never been one to live with regrets and I wasn’t about to start that thought process as the result of a new diagnosis,' Jean explained. 'Plus, I can do things that I never would have even considered before, so I have no reason to be angry or upset. I’m just so darn happy!' 
Night out: Jean was wearing heels six months after she started taking L-Dopa to relieve her muscle spasms and tremors 
Night out: Jean was wearing heels six months after she started taking L-Dopa to relieve her muscle spasms and tremors 


Bing

21 April 2015

ROCHESTER MAYO CLINIC: Plasma Cell Cancer treated by systemic oncolytic therapy.Dept.Mol.Med & Haem. Prof. Stephen J. RUSSELL MBChB (Edin.) PhD(Lond.) FRCP(Lond) FRCPath..(Eng.)

  1. Russell SJ, Federspiel MJ, Peng KW, Tong C, Dingli D, Morice WG, Lowe V, O'Connor MK, Kyle RA, Leung N, Buadi FK, Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc. 2014 Jul; 89(7):926-33. Epub 2014 May 14.
    View PubMed
DAILY MAIL UK

Could measles cure cancer? Experimental virus treatment leaves 49 year old woman in complete remission

  • Two patients underwent the treatment, which researchers stress was at the earliest stage of human trials
  • Were injected with high dose of an engineered version of the measles virus
  • 49-year-old woman now in complete remission